Lee's Pharmaceutical Holdings Limited (FRA:L1PA)

Germany · Delayed Price · Currency is EUR

0.1130

+0.0010 (0.89%)

Last updated: Aug 26, 2026, 3:25 PM CET

-46.70% (1Y)

Market Cap	72.21M -44.6%
Revenue (ttm)	157.13M +2.6%
Net Income	10.06M -1.2%
EPS	0.02 -1.3%
Shares Out	n/a
PE Ratio	7.18
Forward PE	n/a
Dividend	0.00 (4.30%)
Ex-Dividend Date	May 27, 2026

Volume	6
Open	0.1120
Previous Close	0.1120
Day's Range	0.1120 - 0.1130
52-Week Range	0.1040 - 0.2700
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About FRA:L1PA

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to trea... [Read more]

Industry Pharmaceutical Preparations

Founded 1994

Employees 1,094

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol L1PA

Financial Performance

In 2025, FRA:L1PA's revenue was 1.44 billion, an increase of 2.57% compared to the previous year's 1.40 billion. Earnings were 91.94 million, a decrease of -1.25%.

Financial numbers in HKD Financial Statements